BiomX (PHGE) EPS (Basic) : $-0.61 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BiomX EPS (Basic)?

BiomX's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.28. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.61.

BiomX's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.61.

BiomX's EPS without NRI for the three months ended in Mar. 2024 was $-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.53.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

BiomX EPS (Basic) Historical Data

The historical data trend for BiomX's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiomX EPS (Basic) Chart

BiomX Annual Data

Trend

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

0.15

-1.30

-1.39

-0.95

-0.51

BiomX Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-0.20	-0.12	-0.13	-0.08	-0.28

BiomX EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BiomX's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-26.169	-	0)	/	51.330
	=	-0.51

BiomX's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-17.327	-	0)	/	62.292
	=	-0.28

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61

BiomX (AMEX:PHGE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BiomX EPS (Basic) Related Terms

Thank you for viewing the detailed overview of BiomX's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

BiomX (PHGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiomX Inc (AMEX:PHGE) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003

Website

https://www.biomx.com

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.

Executives

Assaf Oron	officer: Chief Business Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Michael E. Dambach	director	22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003
Jason M. Marks	director	C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Carl L Gordon	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Biofund Gp Limited Partnership	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Chidozie Ugwumba	10 percent owner	158 FILMORE STREET, DENVER CO 80206
Thomas Layton Walton	10 percent owner	P.O. BOX 1860, BENTONVILLE AR 72712
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Lynne Marie Sullivan	director	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Marina Wolfson	officer: Principal Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Jonathan Eitan Solomon	director, officer: Chief Executive Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Russell Greig	director	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004